- Home
- BTDR vs AGIO Comparison
BTDR vs AGIO Comparison
Compare BTDR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTDR
- AGIO
- Stock Information
- Founded
- BTDR 2021
- AGIO 2007
- Country
- BTDR Singapore
- AGIO United States
- Employees
- BTDR N/A
- AGIO N/A
- Industry
- BTDR EDP Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- BTDR Technology
- AGIO Health Care
- Exchange
- BTDR Nasdaq
- AGIO Nasdaq
- Market Cap
- BTDR 2.0B
- AGIO 2.0B
- IPO Year
- BTDR N/A
- AGIO 2013
- Fundamental
- Price
- BTDR $8.83
- AGIO $29.30
- Analyst Decision
- BTDR Strong Buy
- AGIO Buy
- Analyst Count
- BTDR 9
- AGIO 8
- Target Price
- BTDR $19.83
- AGIO $56.57
- AVG Volume (30 Days)
- BTDR 4.2M
- AGIO 593.1K
- Earning Date
- BTDR 05-12-2025
- AGIO 05-01-2025
- Dividend Yield
- BTDR N/A
- AGIO N/A
- EPS Growth
- BTDR N/A
- AGIO N/A
- EPS
- BTDR N/A
- AGIO 11.64
- Revenue
- BTDR $349,782,000.00
- AGIO $36,498,000.00
- Revenue This Year
- BTDR $81.46
- AGIO $50.61
- Revenue Next Year
- BTDR $99.77
- AGIO $223.79
- P/E Ratio
- BTDR N/A
- AGIO $2.52
- Revenue Growth
- BTDR N/A
- AGIO 36.07
- 52 Week Low
- BTDR $5.23
- AGIO $27.14
- 52 Week High
- BTDR $26.99
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- BTDR 36.86
- AGIO 35.86
- Support Level
- BTDR $9.56
- AGIO $30.00
- Resistance Level
- BTDR $11.79
- AGIO $32.90
- Average True Range (ATR)
- BTDR 0.78
- AGIO 1.25
- MACD
- BTDR 0.10
- AGIO -0.15
- Stochastic Oscillator
- BTDR 11.11
- AGIO 20.80
About BTDR Bitdeer Technologies Group
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.